+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antibody Therapeutics Market by Format, Route of Administration, Source, Disease Areas, Application, End-User - Global Forecast to 2030- Product Image
Antibody Therapeutics Market by Format, Route of Administration, Source, Disease Areas, Application, End-User - Global Forecast to 2030- Product Image
Sale

Antibody Therapeutics Market by Format, Route of Administration, Source, Disease Areas, Application, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924893
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Antibody Therapeutics Market grew from USD 256.28 billion in 2024 to USD 287.58 billion in 2025. It is expected to continue growing at a CAGR of 12.45%, reaching USD 518.32 billion by 2030.

Executive Summary: Introduction to the Antibody Therapeutics Landscape

Antibody therapeutics have revolutionized modern medicine by offering highly specific, effective treatment options across a broad range of diseases. Since the approval of the first monoclonal antibody in the 1980s, continuous innovation has propelled this class into a cornerstone of precision therapy. Today’s portfolio spans formats from classic monoclonal antibodies to next-generation constructs designed to enhance potency, reduce off-target effects, and improve patient convenience. As the global population ages and chronic conditions rise, the demand for safe and targeted biologics intensifies. This executive summary provides a clear overview of the current landscape, highlights the forces driving transformation, and equips decision-makers with actionable insights to navigate opportunities and challenges in antibody therapeutics.

Transformative Technological and Therapeutic Shifts

In recent years, the antibody therapeutics field has experienced transformative shifts that extend well beyond incremental improvements. Advances in protein engineering have given rise to bispecific antibodies capable of engaging two targets simultaneously, unlocking novel mechanisms of action against complex diseases. Antibody-drug conjugates now deliver potent cytotoxins directly to tumor cells with unprecedented selectivity. Meanwhile, subcutaneous formulations and self-administered delivery systems are shifting treatment from the clinic into patients’ homes, enhancing adherence and reducing healthcare burdens. Artificial intelligence and machine learning tools accelerate lead identification by predicting antigen-antibody interactions and optimizing developability. Together, these trends are redefining pipeline strategies, creating new business models, and setting a higher bar for safety, efficacy, and patient-centric design in the years ahead.

Cumulative Impact of 2025 United States Tariffs on Supply Chains

The implementation of new United States tariffs in 2025 has introduced cost pressures across the antibody therapeutics value chain. Increased duties on imported biologics manufacturing equipment and critical raw materials have prompted several manufacturers to re-evaluate supply agreements and explore nearshoring opportunities. These adjustments are not limited to cost containment; they also influence regulatory planning, inventory strategies, and long-term partnerships. In response, some organizations are deepening collaborations with domestic suppliers, while others diversify sourcing to mitigate exposure. The net effect is a more resilient but complex supply network that balances geopolitical risk with the imperative to deliver life-saving therapies on schedule.

Key Segmentation Insights Driving Strategic Focus

Understanding key market segments is essential for tailoring R&D investments and commercial strategies. Based on format, the landscape ranges from small antibody fragments to highly engineered antibody-drug conjugates, bispecific constructs, full-length monoclonal antibodies, and polyclonal mixtures, each offering unique therapeutic profiles and manufacturing considerations. When viewed through the lens of route of administration, intravenous infusions continue to dominate hospital settings, while subcutaneous options gain traction in specialty clinics and home care. Source categorization reveals a balance between chimeric, human, and humanized antibodies, reflecting ongoing efforts to enhance safety and reduce immunogenicity. Disease area segmentation spans autoimmune and inflammatory conditions, hematology, immunology, neurology, oncology, osteology, and rare diseases, highlighting where unmet need and clinical opportunity intersect. Application insights cover diagnostics, research tools, and therapeutic use, emphasizing the dual roles antibodies play in discovery and patient care. Finally, end-user segmentation-hospitals, research institutes, and specialty clinics-underscores how each stakeholder’s requirements shape product design, regulatory pathways, and market access tactics.

Key Regional Insights and Market Dynamics

Regional dynamics play a pivotal role in shaping antibody therapeutics strategies and partnerships. In the Americas, robust investment in R&D, strong reimbursement frameworks, and streamlined regulatory processes facilitate rapid clinical advancement and early access programs. The Europe, Middle East & Africa region balances mature markets with emerging economies; here, harmonization efforts and public-private initiatives drive adoption, while cost containment and centralized procurement shape pricing models. Asia-Pacific is characterized by accelerated biotechnology growth, increasing local manufacturing capacity, and supportive government policies that prioritize innovation hubs in China, Japan, India, and Australia. Together, these regional nuances inform go-to-market approaches, partnership structures, and lifecycle management plans for biologic developers.

Key Company Strategies and Competitive Landscape

Leading biopharmaceutical companies are leveraging diverse strategies to maintain competitive advantage. Global innovators are investing heavily in next-generation platforms such as bispecific antibodies and antibody-drug conjugates, while forging collaborations with biotech specialists to expand their technology portfolios. Some are prioritizing vertical integration by acquiring contract manufacturing organizations to secure capacity and streamline supply. Mid-sized players focus on niche indications and rare diseases, using flexible development models to advance candidates rapidly. Across the board, the emphasis on digital transformation-from laboratory automation to real-world evidence analytics-facilitates data-driven decision-making. These strategic moves underscore the importance of agility, collaboration, and technological leadership in a market where scientific breakthroughs and commercial execution must align seamlessly.

Actionable Recommendations for Industry Leaders

To capitalize on these developments, industry leaders should prioritize investment in modular manufacturing platforms that support rapid format switching and scale-up, ensuring supply agility in the face of regulatory or tariff-related shifts. They must also strengthen partnerships with regional stakeholders-academic centers, contract manufacturers, and payers-to accelerate clinical adoption and optimize market access. Integration of AI-driven discovery tools can shorten lead selection timelines, but success requires parallel investment in in-house data science expertise. Companies should adopt value-based pricing models, tying outcomes to reimbursement, particularly in health systems under cost pressure. Finally, proactive engagement with regulators and policy makers on tariff implications and material standards will help secure long-term stability and guard against unexpected disruptions.

Research Methodology: Ensuring Rigor and Relevance

This report was developed through a rigorous two-pronged research approach. First, comprehensive secondary research encompassed peer-reviewed journals, patent databases, company filings, regulatory agency publications, and industry white papers to map existing technologies, regulatory requirements, and competitive activity. Second, primary research included structured interviews and surveys with key opinion leaders, C-suite executives, manufacturing experts, and reimbursement specialists across major markets. Data triangulation and cross-validation ensured the reliability of insights, while an iterative review process with subject matter experts guaranteed technical accuracy and relevance. Quality control measures, including editorial peer review and consistency checks, were applied throughout to deliver an authoritative and actionable analysis.

Conclusion: Navigating the Future of Antibody Therapeutics

In conclusion, the antibody therapeutics sector stands at the intersection of scientific innovation and evolving market dynamics. Technological breakthroughs are expanding therapeutic possibilities, even as supply chains adapt to geopolitical and economic pressures. By leveraging detailed segmentation, regional intelligence, and competitive benchmarking, stakeholders can identify strategic priorities, mitigate risks, and accelerate patient access to cutting-edge therapies. The future of antibody therapeutics will be shaped by those who can seamlessly integrate discovery, development, and commercialization in a landscape defined by both complexity and promise.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Format
    • Antibody Fragments
    • Antibody-Drug Conjugates (ADCs)
    • Bispecific Antibody
    • Monoclonal Antibody
    • Polyclonal Antibody
  • Route of Administration
    • Intravenous
    • Subcutaneous
  • Source
    • Chimeric
    • Human
    • Humanized
  • Disease Areas
    • Autoimmune & Inflammatory Diseases
    • Hematology
    • Immunology
    • Neurology
    • Oncology
    • Osteology
    • Rare Diseases
  • Application
    • Diagnostics
    • Research
    • Therapeutics
  • End-User
    • Hospitals
    • Research Institutes
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • AbCellera Biologics Inc.
  • Adaptimmune Therapeutics PLC
  • ADC Therapeutics SA
  • Aenova Holding GmbH
  • Almac Group Limited
  • Amgen Inc.
  • Antikor Biopharma
  • Argenx SE
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Confo Therapeutics
  • DH Life Sciences, LLC
  • DotBio Pte. Ltd.
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies, Inc.
  • Genmab A/S
  • GlaxoSmithKline PLC
  • Grifols, S.A.
  • Incyte Corporation
  • iTeos Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Merus N.V.
  • MoonLake Immunotherapeutics AG
  • MorphoSys AG
  • Novartis AG
  • Novo Nordisk A/S
  • Numab Therapeutics AG
  • Pfizer Inc.
  • PharmAbcine Inc.
  • Pyxis Oncology, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • SAB Biotherapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • TRIO Pharmaceuticals Inc.
  • UCB S.A.
  • Xencor, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Current Landscape and Evolution of the Antibody Therapeutics Market Shaping Industry Significance
3.2. Consumer Drivers, Product Strategy Dichotomy, and Regional Regulatory Impact in Antibody Therapeutics
3.3. Market Lifecycle, Intellectual Property Dynamics, and Strategic Roadmap for Sustained Advantage
3.4. Future Market Trajectory, Strategic Growth Pathways, and Emerging Technological Opportunities
4. Market Overview
4.1. Introduction
4.1.1. Charting the Antibody Therapeutics Market and Emerging Growth Drivers
4.1.2. Regional Dynamics Shaping Global Antibody Therapeutic Penetration
4.1.3. Recent Breakthroughs and Strategic Expansions in Antibody Therapeutics
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advancements in antibody-drug conjugate linkers driving higher payload stability in solid tumors
5.1.1. Defining Next-Generation ADC Linkers for Solid Tumor Payload Stability
5.1.2. Transforming Oncology Pipelines through Enhanced Conjugation Strategies
5.1.3. Future Pathways and Strategic Considerations for ADC Linker Innovation
5.2. Integration of AI-driven discovery platforms accelerating novel antibody candidate optimization
5.2.1. Unveiling the AI-Powered Revolution in Antibody Discovery
5.2.2. Transforming Therapeutic Pipelines Through AI Optimization
5.2.3. Charting the Future of AI-Accelerated Antibody Development
5.3. Expanded application of immunomodulatory antibodies in autoimmune disorders beyond oncology
5.3.1. From Oncology Success to Autoimmune Impact: Drivers of Immunomodulatory Antibody Expansion
5.3.2. Strategic Imperatives for Adapting to the Autoimmune Antibody Revolution
5.3.3. Navigating the Next Phase: Future Trajectory of Immunomodulatory Antibodies in Autoimmunity
5.4. Enhancing bispecific antibody design to improve targeted tumor destruction and safety profiles
5.4.1. Defining Next-Gen Bispecific Antibody Engineering
5.4.2. Transforming Oncology Pipelines with Dual-Targeting Innovations
5.4.3. Navigating the Future of Bispecific Therapeutic Development
5.5. Growth of subcutaneous and intramuscular antibody formulations boosting patient adherence
5.5.1. Accelerating Adoption of Subcutaneous and Intramuscular Antibodies
5.5.2. Strategic Imperatives for Embracing Patient-Centric Formulations
5.5.3. Navigating the Future Trajectory of Administration Innovation
5.6. Impact of biosimilar competition on pricing strategies and market access for established mAb therapies
5.6.1. Defining the Biosimilar Disruption in Monoclonal Antibody Markets
5.6.2. Competitive Pricing Dynamics Fueling Market Transformation
5.6.3. Navigating Future Risks and Strategic Responses
5.7. Novel bispecific antibody engineering strategies enhance precise tumor targeting and safety profiles
5.7.1. Unpacking Bispecific Antibody Innovations for Precision Tumor Targeting
5.7.2. How Bispecific Designs Are Driving Therapeutic Innovation and Market Expansion
5.7.3. Anticipating the Evolution and Risks of Advanced Bispecific Antibodies
5.8. Next-generation antibody-drug conjugate linkers improve payload stability and therapeutic index in solid tumors
5.8.1. Enhancing Solid Tumor ADCs Through Advanced Linker Technology
5.8.2. Strategic Imperatives for Biotech and Pharma in the Next-Gen ADC Landscape
5.8.3. Projected Trajectory of Linker Innovations in Solid Tumor Therapies
5.9. Expanding the use of immunomodulatory antibodies to manage autoimmune diseases beyond oncology settings
5.9.1. Broadening Immunotherapy Horizons into Autoimmune Care
5.9.2. Adaptation Strategies for Antibody Developers in Autoimmune Markets
5.9.3. Projected Evolution of Immunomodulatory Antibody Trends
5.10. Strategies to navigate biosimilar competition and preserve market access for established monoclonal therapies
5.10.1. Decoding Biosimilar Competition and Its Impact on Established Monoclonal Therapies
5.10.2. Adapting Commercial and Operational Models to Biosimilar Challenges
5.10.3. Long Term Outlook for Monoclonal Antibody Strategies in a Biosimilar Era
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.1.1. Towering Obstacles Keep New Competitors at Bay
6.1.2. Alternative Modalities Shape Competitive Terrain
6.1.3. Supply Chain Concentration Influences Bargaining Strength
6.1.4. Payers and Providers Drive Pricing Dynamics
6.1.5. Rivalry Intensifies Through Innovation and Pipeline Battles
6.2. PESTLE Analysis
6.2.1. Regulatory Shifts and Global Health Policy Dynamics
6.2.2. Funding Landscape and Reimbursement Pressures
6.2.3. Aging Populations and Patient Expectations
6.2.4. Advances in Bioprocessing and Digital Diagnostics
6.2.5. Intellectual Property Battles and Regulatory Compliance Demands
6.2.6. Sustainability Requirements and Supply Chain Resilience
7. Cumulative Impact of United States Tariffs 2025
7.1. Overview of US Tariffs Reshaping the Industry Landscape
7.2. Evolution of US Trade Policies and Economic Motivations
7.3. How Tariffs Have Fueled Inflationary Pressures Globally
7.4. Reciprocal Tariffs and Escalating Trade Conflicts
7.5. Consequences for Key Trading Partners’ Economies and Politics
7.6. Supply Chain Realignments and Consumer Impact in the US
7.7. Strategic Policy Options to Alleviate Tariff Burdens
8. Antibody Therapeutics Market, by Format
8.1. Introduction
8.2. Antibody Fragments
8.3. Antibody-Drug Conjugates (ADCs)
8.4. Bispecific Antibody
8.5. Monoclonal Antibody
8.6. Polyclonal Antibody
9. Antibody Therapeutics Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Subcutaneous
10. Antibody Therapeutics Market, by Source
10.1. Introduction
10.2. Chimeric
10.3. Human
10.4. Humanized
11. Antibody Therapeutics Market, by Disease Areas
11.1. Introduction
11.2. Autoimmune & Inflammatory Diseases
11.3. Hematology
11.4. Immunology
11.5. Neurology
11.6. Oncology
11.7. Osteology
11.8. Rare Diseases
12. Antibody Therapeutics Market, by Application
12.1. Introduction
12.2. Diagnostics
12.3. Research
12.4. Therapeutics
13. Antibody Therapeutics Market, by End-User
13.1. Introduction
13.2. Hospitals
13.3. Research Institutes
13.4. Specialty Clinics
14. Americas Antibody Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Antibody Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Antibody Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.1.1. Forging Global Position in Antibody Therapeutics through Strategic Innovation
17.3.1.2. Transformative Antibody Therapies Redefining Patient Care
17.3.1.3. Mitigating Risks and Seizing Next-Generation Growth Opportunities
17.3.2. AbCellera Biologics Inc.
17.3.2.1. From Startup to Global Antibody Discovery Powerhouse
17.3.2.2. Bamlanivimab to Next-Gen Platforms Redefining Therapeutic Precision
17.3.2.3. Addressing Risks and Unlocking Strategic Growth Pathways
17.3.3. Adaptimmune Therapeutics PLC
17.3.3.1. Charting the Rise from Startup to Specialty Challenger
17.3.3.2. Inside Adaptimmune’s SPEAR T-Cell Arsenal
17.3.3.3. Mitigating Risks to Secure Long-Term Leadership
17.3.4. ADC Therapeutics SA
17.3.4.1. Establishing Market Presence as an ADC Innovator
17.3.4.2. Distinctive ADC Portfolio Underpinning Clinical Leadership
17.3.4.3. Navigating Risks and Harnessing Emerging Oncology Opportunities
17.3.5. Aenova Holding GmbH
17.3.5.1. Anchoring Leadership in Biopharmaceutical Contract Manufacturing
17.3.5.2. Integrated Antibody Therapeutics Manufacturing Solutions Driving Client Success
17.3.5.3. Mitigating Operational Risks and Unlocking Future Growth Pathways
17.3.6. Almac Group Limited
17.3.6.1. Almac’s Strategic Pillars and Market Footprint
17.3.6.2. Integrated Antibody Therapeutics Offerings Driving Client Success
17.3.6.3. Navigating Risks with Strategic Innovation and Diversification
17.3.7. Amgen Inc.
17.3.7.1. Amgen’s Strategic Position and Market Footprint
17.3.7.2. High-Impact Antibody Therapies Driving Commercial Leadership
17.3.7.3. Mitigating Risks and Accelerating Future Growth
17.3.8. Antikor Biopharma
17.3.8.1. Establishing Leadership in Next-Gen Antibody Therapeutics
17.3.8.2. Driving Innovation Through High-Impact Antibody Platforms
17.3.8.3. Navigating Risks and Seizing Strategic Growth Levers
17.3.9. Argenx SE
17.3.9.1. From Inception to Influence: Argenx’s Market Entry and Positioning
17.3.9.2. Flagship Innovation: Core Antibody Therapeutics Driving Growth
17.3.9.3. Navigating Risks: Strategic Imperatives to Fortify Argenx’s Growth
17.3.10. Astellas Pharma Inc.
17.3.10.1. Astellas Pharma’s Market Position and Core Strength
17.3.10.2. Flagship Antibody Therapies Driving Market Differentiation
17.3.10.3. Mitigating Risks and Seizing Growth Opportunities
17.3.11. AstraZeneca PLC
17.3.11.1. From Merger Genesis to Market Leadership: AstraZeneca’s Strategic Evolution
17.3.11.2. Precision Biologics Portfolio Delivering Unmatched Clinical Impact
17.3.11.3. Mitigating Headwinds with Strategic Partnerships and Operational Resilience
17.3.12. Baxter International Inc.
17.3.12.1. Trailblazing Beginnings to Market Leadership: Baxter's Antibody Therapeutics Journey
17.3.12.2. Transformative Antibody Portfolio: Deep Dive into Baxter's Flagship Offerings
17.3.12.3. Navigating Risks and Fortifying Baxter's Antibody Growth Roadmap
17.3.13. Bayer AG
17.3.13.1. Forging a Leader’s Path from Collaboration to Global Antibody Impact
17.3.13.2. Eylea Excellence Reinventing Antibody Therapy for Retinal Disease
17.3.13.3. Securing Tomorrow Addressing Biosimilars and R&D Gaps to Fortify Growth
17.3.14. Becton, Dickinson and Company
17.3.14.1. Evolution from Needles to Next-Gen Therapeutics Market Leadership
17.3.14.2. Flagship Offerings Driving Antibody Research and Delivery Innovation
17.3.14.3. Navigating Regulatory and Competitive Headwinds for Sustained Growth
17.3.15. Bio-Rad Laboratories, Inc.
17.3.15.1. From Electrophoresis Pioneers to Global Life Science Powerhouse
17.3.15.2. Flagship Innovations Driving Precision and Productivity
17.3.15.3. Navigating Headwinds with Resilient Growth Strategies
17.3.16. Biogen Inc.
17.3.16.1. From Biotech Pioneer to Antibody Therapeutics Leader
17.3.16.2. Flagship Antibody Medicines and Their Differentiating Strengths
17.3.16.3. Navigating Risks: Strengthening Biogen’s Strategic Resilience
17.3.17. BioNTech SE
17.3.17.1. BioNTech’s Pioneering Footprint in Immunotherapy Markets
17.3.17.2. Flagship Innovations Driving Clinical Impact and Differentiation
17.3.17.3. Mitigating Risks and Charting Growth Through Strategic Diversification
17.3.18. Bristol-Myers Squibb Company
17.3.18.1. Forging a Market-Leading Position in Immuno-Oncology
17.3.18.2. Flagship Antibody Therapies Driving Clinical Impact
17.3.18.3. Mitigating Risks and Charting Future Growth Strategies
17.3.19. Confo Therapeutics
17.3.19.1. From Spin-off to Structural Biology Innovator
17.3.19.2. Platform Powerhouse and Flagship Pipeline Assets
17.3.19.3. Navigating Technical, Financial, and Competitive Hurdles
17.3.20. DH Life Sciences, LLC
17.3.20.1. Strategic Footprint and Core Strengths in Antibody Therapeutics
17.3.20.2. Flagship Antibody Solutions Driving Clinical Impact
17.3.20.3. Mitigating Risks and Driving Portfolio Evolution
17.3.21. DotBio Pte. Ltd.
17.3.21.1. DotBio’s Strategic Position as a Leader in Next-Generation Antibody Therapeutics
17.3.21.2. Innovative Therapeutic Platforms Driving Market Differentiation
17.3.21.3. Addressing Critical Risks and Unlocking Strategic Growth Pathways
17.3.22. Eli Lilly and Company
17.3.22.1. From Partnership Roots to Global Antibody Leader
17.3.22.2. Transformative Therapeutics Shaping Patient-Centric Care
17.3.22.3. Navigating Risks and Fortifying Future Growth
17.3.23. Emergent BioSolutions Inc.
17.3.23.1. Emergent BioSolutions’ Journey from Biodefense Pioneer to Competitive Force
17.3.23.2. Core Solutions Spotlight: Vaccines, Therapeutic Antibodies, and Manufacturing Excellence
17.3.23.3. Navigating Risks and Fortifying Future Market Position
17.3.24. Evonik Industries AG
17.3.24.1. Evonik’s Strategic Ascent from Specialty Chemicals to Global Biopharma Service Leader
17.3.24.2. Flagship Bioprocess Platforms Accelerating Antibody and ADC Development Success
17.3.24.3. Mitigating Risks and Fortifying Evonik’s Competitive Edge
17.3.25. F. Hoffmann-La Roche Ltd.
17.3.25.1. Dominating the Biologics Arena with a Global Footprint
17.3.25.2. Signature Antibody Therapies Redefining Patient Care
17.3.25.3. Navigating Challenges to Secure Future Growth
17.3.26. GE HealthCare Technologies, Inc.
17.3.26.1. From Imaging Pioneer to Bioprocessing Powerhouse: GE HealthCare’s Evolution
17.3.26.2. Flagship Platforms Accelerating Antibody Therapeutics Innovation
17.3.26.3. Navigating Headwinds: Risks and Strategic Imperatives for Future Growth
17.3.27. Genmab A/S
17.3.27.1. From Startup to Global Contender in Antibody Therapeutics
17.3.27.2. Inside Genmab’s Flagship Antibody Therapies and Their Edge
17.3.27.3. Navigating Risks and Fortifying Genmab’s Growth Trajectory
17.3.28. GlaxoSmithKline PLC
17.3.28.1. Evolution from Immunology Challenger to Global Antibody Leader
17.3.28.2. Unpacking GSK’s Antibody Portfolio: Precision Meets Patient Needs
17.3.28.3. Navigating Headwinds: Bolstering GSK’s Antibody Edge
17.3.29. Grifols, S.A.
17.3.29.1. From Plasma Origins to Global Biotherapeutics Powerhouse
17.3.29.2. Core Therapies Redefined: Flagship Immunoglobulin and Diagnostic Innovations
17.3.29.3. Navigating Volatility: Risks, Weaknesses, and Strategic Imperatives
17.3.30. Incyte Corporation
17.3.30.1. Anchoring Leadership in Targeted Oncology with Strategic Global Presence
17.3.30.2. Driving Precision Medicine Impact through Flagship Oncology and Immuno-Therapies
17.3.30.3. Addressing Patent Cliffs and Competitive Threats with a Diversified Growth Roadmap
17.3.31. iTeos Therapeutics, Inc.
17.3.31.1. From Bench to Biotech Challenger: iTeos’ Market Entry and Evolving Position
17.3.31.2. Precision Immunotherapy Unveiled: Inside iTeos’ Flagship Antibody Portfolio
17.3.31.3. Navigating Stormy Waters: Risks Confronting iTeos and Strategic Pathways Forward
17.3.32. Johnson & Johnson Services, Inc.
17.3.32.1. Establishing Leadership in Antibody Therapeutics through Strategic Innovation
17.3.32.2. Flagship Antibody Platforms Driving Patient-Centric Solutions
17.3.32.3. Addressing Risks and Leveraging Opportunities for Sustainable Growth
17.3.33. Merck KGaA
17.3.33.1. Evolution of Merck KGaA’s Antibody Therapeutics Strategy
17.3.33.2. Spotlight on Leading Antibody Platforms and Breakthrough Therapies
17.3.33.3. Addressing Risks and Charting a Resilient Growth Path
17.3.34. Merus N.V.
17.3.34.1. Merus’s Rising Influence: Strategic Position and Core Strength
17.3.34.2. Flagship Bispecific Antibodies: Merus’s Differentiation and Clinical Impact
17.3.34.3. Navigating Risks and Charting Growth: Strategic Pathways for Merus
17.3.35. MoonLake Immunotherapeutics AG
17.3.35.1. Charting MoonLake’s Ascent in Immunotherapeutics
17.3.35.2. Dissecting the Tetraspecific Edge of MoonLake’s Flagship Antibodies
17.3.35.3. Navigating Risks and Seizing Growth Pathways for Immuno-Oncology Leadership
17.3.36. MorphoSys AG
17.3.36.1. From Biotech Startup to Immunotherapy Contender: MorphoSys’s Evolution
17.3.36.2. Innovative Antibody Solutions: Dissecting MorphoSys’s Flagship Offerings
17.3.36.3. Navigating Risks and Reinforcing Growth: Strategic Imperatives for MorphoSys
17.3.37. Novartis AG
17.3.37.1. Novartis’ Strategic Leadership in Antibody Therapeutics
17.3.37.2. Flagship Antibody Portfolio and Differentiating Strengths
17.3.37.3. Mitigating Risks and Future-Proofing Through Innovation
17.3.38. Novo Nordisk A/S
17.3.38.1. Pioneering Global Leadership in Diabetes and Obesity Care
17.3.38.2. Breakthrough GLP-1 Therapies Transforming Patient Outcomes
17.3.38.3. Strategic Imperatives to Mitigate Risks and Drive Diversification
17.3.39. Numab Therapeutics AG
17.3.39.1. From Niche Biotech to Global Challenger: Numab’s Market Entry and Rise
17.3.39.2. Tailored Antibody Platforms: Deep Dive into Numab’s Flagship Offerings
17.3.39.3. Navigating Risks and Fortifying Growth: Strategic Imperatives for Numab
17.3.40. Pfizer Inc.
17.3.40.1. Global Leadership Anchored by Innovative Research and Strategic Alliances
17.3.40.2. High-Impact Therapeutics Driving Patient Outcomes and Market Differentiation
17.3.40.3. Mitigating Headwinds Through Diversification and Next-Gen Innovation
17.3.41. PharmAbcine Inc.
17.3.41.1. Navigating the Antibody Therapeutics Landscape: PharmAbcine’s Ascent
17.3.41.2. Empowering Precision Care: The Unique Appeal of PharmAbcine’s Flagships
17.3.41.3. Fortifying Growth: Addressing Risks and Charting Strategic Pathways
17.3.42. Pyxis Oncology, Inc.
17.3.42.1. Protease-Activated Therapies Power Pyxis Oncology’s Market Debut
17.3.42.2. Probody Oncology Candidates Anchor Pyxis’s Therapeutic Edge
17.3.42.3. Mitigating Clinical and Financial Hurdles to Fortify Growth
17.3.43. Regeneron Pharmaceuticals, Inc.
17.3.43.1. From Pioneer to Leader: Regeneron’s Ascent in Antibody Therapeutics
17.3.43.2. Transformative Therapeutics: The Impact of EYLEA and Dupixent
17.3.43.3. Shoring Up Future Growth: Addressing Risks and Bolstering the Pipeline
17.3.44. SAB Biotherapeutics, Inc.
17.3.44.1. Harnessing Transchromosomic Innovation to Redefine Polyclonal Antibody Therapeutics
17.3.44.2. DiversitAb and Beyond: Pioneering Broad-Spectrum Antibody Solutions
17.3.44.3. Navigating Regulatory, Competitive, and Technological Waters for Sustainable Growth
17.3.45. Sanofi S.A.
17.3.45.1. Sanofi’s Strategic Pillars and Global Reach
17.3.45.2. Flagship Antibody Therapies Driving Market Leadership
17.3.45.3. Navigating Risks and Charting a Resilient Growth Path
17.3.45.4. Implementing Strategic Initiatives for Future Resilience
17.3.46. Takeda Pharmaceutical Company Limited
17.3.46.1. Takeda’s Global Leadership and Strategic Footprint in Antibody Therapeutics
17.3.46.2. Flagship Antibody Platforms Driving Therapeutic Innovation
17.3.46.3. Navigating Risks and Charting Strategic Growth Pathways
17.3.47. Thermo Fisher Scientific Inc.
17.3.47.1. From Reagent Roots to CDMO Leadership
17.3.47.2. Integrated Discovery to Commercial-Scale Manufacturing
17.3.47.3. Addressing Competitive Pressures and Operational Risks
17.3.48. TRIO Pharmaceuticals Inc.
17.3.48.1. Pioneering Precision Immunotherapy with Strategic Market Footprint
17.3.48.2. Transformative Antibody Platforms Driving Clinical and Commercial Success
17.3.48.3. Navigating Risk Landscape to Fortify Future Growth and Innovation
17.3.49. UCB S.A.
17.3.49.1. Anchoring Presence: UCBs Strategic Position in Global Antibody Therapeutics
17.3.49.2. Championing Breakthroughs in Patient Care with UCBs Antibody Portfolio
17.3.49.3. Navigating Headwinds Towards Sustainable Growth for UCB
17.3.50. Xencor, Inc.
17.3.50.1. From Engineered Antibody Platform Pioneer to Strategic Market Contender
17.3.50.2. Bispecific and Fc-Engineered Leaders Rewriting Therapeutic Standards
17.3.50.3. Mitigating Clinical and Competitive Threats to Secure Long-Term Growth
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. ANTIBODY THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. ANTIBODY THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY FRAGMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ANTIBODY-DRUG CONJUGATES (ADCS), BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY BISPECIFIC ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OSTEOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 52. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 53. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 56. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. MEXICO ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 74. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 81. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 86. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 87. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 89. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 90. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. GERMANY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 92. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 93. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 95. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 96. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. FRANCE ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 99. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 101. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 102. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. RUSSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 104. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 105. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 107. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 108. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. ITALY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 111. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 113. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 114. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. SPAIN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 116. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 117. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 119. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 120. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 121. UNITED ARAB EMIRATES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. SAUDI ARABIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 132. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. SOUTH AFRICA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 135. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 137. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 138. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. DENMARK ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 141. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 143. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 144. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. NETHERLANDS ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 147. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 149. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 150. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. QATAR ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 152. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 153. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 155. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 156. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. FINLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 159. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 161. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 162. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. SWEDEN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 165. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 166. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 168. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 171. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 173. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 174. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. EGYPT ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 177. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 180. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. TURKEY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 188. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 189. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 191. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 192. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. NORWAY ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 195. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 197. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 198. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. POLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 200. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 201. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 202. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 203. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 204. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. SWITZERLAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 213. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 214. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 216. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 217. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. CHINA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 220. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 222. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 223. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. INDIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 226. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 228. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 229. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 230. JAPAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 244. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 246. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 247. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 248. INDONESIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 249. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 250. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 252. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 253. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. THAILAND ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 255. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 256. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 258. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 259. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. PHILIPPINES ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 268. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 270. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 271. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 272. SINGAPORE ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. VIETNAM ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 279. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 280. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
TABLE 282. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY DISEASE AREAS, 2018-2030 (USD MILLION)
TABLE 283. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 284. TAIWAN ANTIBODY THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
TABLE 286. ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Antibody Therapeutics market report include:
  • AbbVie Inc.
  • AbCellera Biologics Inc.
  • Adaptimmune Therapeutics PLC
  • ADC Therapeutics SA
  • Aenova Holding GmbH
  • Almac Group Limited
  • Amgen Inc.
  • Antikor Biopharma
  • Argenx SE
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Baxter International Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biogen Inc.
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • Confo Therapeutics
  • DH Life Sciences, LLC
  • DotBio Pte. Ltd.
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies, Inc.
  • Genmab A/S
  • GlaxoSmithKline PLC
  • Grifols, S.A.
  • Incyte Corporation
  • iTeos Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Merus N.V.
  • MoonLake Immunotherapeutics AG
  • MorphoSys AG
  • Novartis AG
  • Novo Nordisk A/S
  • Numab Therapeutics AG
  • Pfizer Inc.
  • PharmAbcine Inc.
  • Pyxis Oncology, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • SAB Biotherapeutics, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.
  • TRIO Pharmaceuticals Inc.
  • UCB S.A.
  • Xencor, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 287.58 Billion
Forecasted Market Value ( USD ) by 2030 $ 518.32 Billion
Compound Annual Growth Rate12.4%
Regions CoveredGlobal
No. of Companies Mentioned51

Related Topics

Related Reports

Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Biosimilar Monoclonal Antibodies Market by Molecule Class, Indication, Dosage Form, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Monoclonal Antibody Therapeutics Market by Indication, Antibody Type, Molecular Target, Production Technology, Route of Administration, Distribution Channel, End User, Therapy Type - Global Forecast to 2030 - Product Image

Monoclonal Antibody Therapeutics Market by Indication, Antibody Type, Molecular Target, Production Technology, Route of Administration, Distribution Channel, End User, Therapy Type - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global
From
Bispecific Antibody Therapeutics Contract Manufacturing - Global Strategic Business Report - Product Image

Bispecific Antibody Therapeutics Contract Manufacturing - Global Strategic Business Report

  • Report
  • 382 Pages
  • Global
From
Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cancer Monoclonal Antibodies - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Antibody Discovery Market Industry Trends and Global Forecasts to 2035, by Type of Service Offered, Antibody Discovery Method, Type of Antibody Generated, Nature of Antibody Generated, Type of Therapeutic Areas and Key Geographies - Product Image

Antibody Discovery Market Industry Trends and Global Forecasts to 2035, by Type of Service Offered, Antibody Discovery Method, Type of Antibody Generated, Nature of Antibody Generated, Type of Therapeutic Areas and Key Geographies

  • Report
  • 525 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.